Drug news
NICE now recommends Daxas (roflumilast) to treat severe COPD.- AstraZeneca
The UK National Institute for Health and Care Excellence (NICE) has reversed an earlier decision and now recommends Daxas (roflumilast) from AstraZeneca to treat adults with severe COPD. The decision was based on new evidence that the drug eased symptoms that were not being controlled by inhalers. The drug is recommended for adults with COPD whose symptoms continue to worsen after treatment.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.